JP2005500389A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500389A5
JP2005500389A5 JP2003521776A JP2003521776A JP2005500389A5 JP 2005500389 A5 JP2005500389 A5 JP 2005500389A5 JP 2003521776 A JP2003521776 A JP 2003521776A JP 2003521776 A JP2003521776 A JP 2003521776A JP 2005500389 A5 JP2005500389 A5 JP 2005500389A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
disease
soluble
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003521776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021324 external-priority patent/WO2003016467A2/en
Publication of JP2005500389A publication Critical patent/JP2005500389A/ja
Publication of JP2005500389A5 publication Critical patent/JP2005500389A5/ja
Pending legal-status Critical Current

Links

JP2003521776A 2001-08-17 2002-08-14 Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 Pending JP2005500389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31357601P 2001-08-17 2001-08-17
US38385102P 2002-05-28 2002-05-28
PCT/US2002/021324 WO2003016467A2 (en) 2001-08-17 2002-08-14 Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass

Publications (2)

Publication Number Publication Date
JP2005500389A JP2005500389A (ja) 2005-01-06
JP2005500389A5 true JP2005500389A5 (https=) 2006-01-05

Family

ID=26978953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521776A Pending JP2005500389A (ja) 2001-08-17 2002-08-14 Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用

Country Status (5)

Country Link
US (1) US20040241164A1 (https=)
EP (1) EP1429805A4 (https=)
JP (1) JP2005500389A (https=)
CA (1) CA2452104A1 (https=)
WO (1) WO2003016467A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2003015691A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
CA2451998A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040146512A1 (en) * 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
EA200501524A1 (ru) * 2003-03-28 2006-06-30 Сентокор, Инк. Антитела против амилоида, композиции, способы и применения
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20110142858A1 (en) * 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP1959996A2 (en) 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
DK2121754T3 (en) * 2007-01-18 2015-02-23 Lilly Co Eli Pegylated amyloid BETA FAB
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2235058A2 (en) * 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
WO2009104736A1 (ja) * 2008-02-22 2009-08-27 財団法人ヒューマンサイエンス振興財団 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP3000481A3 (en) * 2009-07-14 2016-05-11 Mayo Foundation for Medical Education and Research Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
JP2012233002A (ja) * 2012-08-03 2012-11-29 Janssen Alzheimer Immunotherapy 認知の改善における使用のためのアミロイドβ抗体
EP3594240B1 (en) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
US9896772B2 (en) * 2014-03-13 2018-02-20 Innosense Llc Modular chemiresistive sensor
US12345680B1 (en) 2014-03-13 2025-07-01 Innosense Corporation Modular chemiresistive sensor for real-time ethylene monitoring
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
KR20170085595A (ko) 2014-12-10 2017-07-24 제넨테크, 인크. 혈뇌 장벽 수용체 항체 및 사용 방법
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
CN113226283A (zh) 2018-10-04 2021-08-06 罗切斯特大学 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
WO2025250454A1 (en) 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta

Similar Documents

Publication Publication Date Title
JP2005500389A5 (https=)
Alexopoulos Vascular disease, depression, and dementia.
Yamada et al. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Kepe et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy
WO2007068411A3 (en) Therapeutic vaccine
WO2003015691A3 (en) RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
Fymat On dementia and other cognitive disorders
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
Karlsson et al. A randomised, double‐blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2021139874A1 (en) Cognitive disorder prevention and therapy
Johansson et al. [11C]-PIB imaging in patients with Parkinson's disease: preliminary results
JP2009505979A5 (https=)
Zhang et al. Decreased nocturnal heart rate variability and potentially related brain regions in arteriosclerotic cerebral small vessel disease
Saletu et al. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies
Holler et al. Camptocormia in Idiopathic Parkinson’s Disease:[[sup 123] I] β-CIT SPECT and Clinical Characteristics.
Kelley et al. Hyperkinetic movement disorders caused by corpus striatum infarcts: brain MRI/CT findings in three cases
MX2023010626A (es) Anticuerpos anti-amiloide beta n3pglu y usos de estos.
Urban et al. Dysarthria-clumsy hand syndrome due to infarction of the cerebral peduncle
Agarwal et al. Wernekink commissure syndrome with bilateral cerebellar signs and holmes tremor in a patient with a preexisting movement disorder
Santhanam et al. Childhood polyarteritis nodosa presenting as central nervous system vasculitis
DeRight 31.2 Subtypes
Ga et al. Factors associated with a decline in activities of daily living in patients with dementia at geriatric hospitals: a 6 month prospective study